PROs and HRQoL among patients participating in the LATITUDE trial

A newly published paper in The Lancet Oncology has provided early data from the LATITUDE trial on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) for men with newly diagnosed, high-risk, metastatic, castration-naive prostate cancer. … READ MORE …

TAPS as a side effect of taxane-based chemotherapy in men with advanced prostate cancer

TAPS stands for “taxane acute pain syndrome”. It is a recognized side effect of treatment with taxanes like docetaxel and it is usually characterized by muscular pain (myalgia) and joint pain (arthralgia) that starts about 24 to 48 hours after taxane treatment and then lasts for up to about 7 days. … READ MORE …

Major trial confirms value of zoledronic acid dosed every 3 months in preventing pain, SREs

An interesting paper that we managed to miss at the recent annual meeting of the American Society of Clinical Oncology (ASCO) provided the results of a large, randomized clinical trial of the use of zoledronic acid, carried out by the Cancer and Leukemia Group B cooperative trial group. … READ MORE …

A genetic driver of pain in prostate cancer … and other cancers too?

According to a newly published paper in the journal Pain, the presence of a particular genetic marker in cancer cells may be a key factor in risk for cancer-related pain. … READ MORE …

Music (plus lidocaine) soothes the savaged male

A small, randomized, pilot study has shown that music (along with some lidocaine) reduces the anxiety, pain, and dissatisfaction of men having a TRUS-guided biopsy compared to the lidocaine alone. … READ MORE …

Penile pain/urethral discomfort after radical prostatectomy

It comes as no surprise that there is some urethral “discomfort” experienced by patients with an indwelling urethral catheter after a radical prostatectomy (regardless of the type of surgery), and that for some patients there can be a degree of significant penile pain until the catheter is removed (usually within about 8 to 10 days). … READ MORE

When is radiopharmaceutical therapy most appropriately initiated in men with mCRPC?

A newly published paper by a team of Italian researchers has added a wrinkle to the critical questions about the most effective current and future forms of sequential therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …